Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038179 · ClinicalTrials.gov registry record · Phase 2
Center of Research Translation (CORT) Project 2
A Phase 2 study of Pre Hypertension and JNC 7 Stage I Hypertension, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT02038179 is a Phase 2 study of Pre Hypertension and JNC 7 Stage I Hypertension that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 99 participants, above the 49-participant average among 4 other Pre Hypertension trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02038179, a Phase 2 study of Pre Hypertension and JNC 7 Stage I Hypertension, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout. The proposed study is novel in its plans to investigate the physiologic mechanisms through which urate contributes to vascular disease and by which ULT may contribute to BP reduction. Also innovative, we will: 1) determine to what extent the described benefit of lowering serum urate extends beyond the adolescent population previously studied into young adults, 2) test whether a urate-lowering approach will benefit individuals that do not yet meet the current definition of hyperuricemia and do not have gout, and 3) begin to explore potential mechanisms for the higher prevalence of hypertension among African-Americans. If successful, this work could translate to the standard of clinical care and to health care recommendations for the population as a whole.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Allopurinol
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038179
The ClinicalTrials.gov registry entry for NCT02038179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 49-participant average among 4 other Pre Hypertension trials with a reported enrollment target (102% higher). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pre Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02038179 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT02038179 about?
NCT02038179 is a clinical study titled "Center of Research Translation (CORT) Project 2". We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout. The proposed study is novel in its plans to investigate the physiologic mechanisms thro...
What is the current status of trial NCT02038179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2014-07. Estimated completion is 2018-08.
What conditions does trial NCT02038179 study?
This clinical trial studies the following conditions: Pre Hypertension, JNC 7 Stage I Hypertension.
What interventions are being tested in trial NCT02038179?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG).
Who is sponsoring clinical trial NCT02038179?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02038179 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.